Pain Control of Thoracoscopic Major Pulmonary Resection

Pain Control of Thoracoscopic Major Pulmonary Resection: Is Pre-emptive Local Bupivacaine Injection Able to Replace the Intravenous Patient Controlled Analgesia?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01758809

Enrollment

Registered

2013-01-01

Start date

2010-12-31

Completion date

2011-11-30

Last updated

2013-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

Video Assisted Thoracic Surgery, Postoperative Pain, Intravenous Patient Controlled Analgesia, Bupivacaine, Major Pulmonary Resection, Post Pulmonary Resection

Brief summary

The purpose of this study is to evaluate whether pre-emptive local bupivacaine injection is a better alternative pain control modality than the conventional intravenous patient controlled analgesia.

Detailed description

Despite less postoperative pain from Video Assisted Thoracic Surgery (VATS) than thoracotomy, pain is still an important issue in its recovery period. After VATS procedure, intravenous patient controlled analgesia (IV PCA) is being used for pain control. However, the side effects of IV PCA are nausea, vomiting, sleepiness, and urination difficulty which interrupt the early recovery. It is established that pre-emptive local bupivacaine injection is more economical, has almost no side effects, and finally, it is effective for the postoperative 24 hours. The purpose of this study is to evaluate whether pre-emptive local bupivacaine injection is a better alternative pain control modality than the conventional intravenous patient controlled analgesia.

Interventions

PROCEDUREPre-emptive bupivacaine wound infiltration

Pre-emptive bupivacaine wound infiltration

PROCEDUREintravenous patient controlled analgesia

postoperative pain control with intravenous patient controlled analgesia

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients that are expected to receive VATS segmenectomy or lobectomy regardless of disease entity

Exclusion criteria

* not done by VATS anatomical resection * patient does not agree to the study * postoperative hospital stay exceeds 7 days due to postoperative complications * existence of preoperative renal insufficiency (Cr \> 1.5) * OT/PT \> 120 * history of Lidocaine hypersensitivity

Design outcomes

Primary

Measure	Time frame
The change in postoperative pain confirmed by Visual Analogue Pain Scale	Operation day, Postoperative Day 1, 2, 3 and 2 week, 1 month, 2 months

Secondary

Measure	Time frame	Description
number of participants with adverse events related to fentanyl or bupivacaine drug	2 months	nausea, vomiting, sleepiness, urinary difficulty, respiratory depression

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026